Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257


Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.

Bruder JT, Stefaniak ME, Patterson NB, Chen P, Konovalova S, Limbach K, Campo JJ, Ettyreddy D, Li S, Dubovsky F, Richie TL, King CR, Long CA, Doolan DL.

Vaccine. 2010 Apr 19;28(18):3201-10. doi: 10.1016/j.vaccine.2010.02.024.


Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, Limsalakpetch A, Stewart VA, Lanar DE, Dutta S, Angov E, Ware LA, Bergmann-Leitner ES, House B, Voss G, Dubois MC, Cohen JD, Fukuda MM, Heppner DG, Miller RS.

Vaccine. 2009 Dec 11;28(2):452-62. doi: 10.1016/j.vaccine.2009.10.022.


In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW.

Infect Immun. 2002 Dec;70(12):6948-60.


Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.

Lalitha PV, Biswas S, Pillai CR, Saxena RK.

Vaccine. 2008 Aug 18;26(35):4526-35. doi: 10.1016/j.vaccine.2008.06.031.


Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.

Xue X, Ding F, Zhang Q, Pan X, Qu L, Pan W.

Vaccine. 2010 Apr 19;28(18):3152-8. doi: 10.1016/j.vaccine.2010.02.054.


Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.

Yoshida S, Nagumo H, Yokomine T, Araki H, Suzuki A, Matsuoka H.

PLoS One. 2010 Oct 28;5(10):e13727. doi: 10.1371/journal.pone.0013727.


Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.

Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH.

Infect Immun. 2002 Dec;70(12):6961-7.


Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.

Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, Martin LB, Pierce MA, Ellis RD, Mullen GE, Long CA.

Clin Vaccine Immunol. 2009 Jul;16(7):963-8. doi: 10.1128/CVI.00042-09.


Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.

Elias SC, Choudhary P, de Cassan SC, Biswas S, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Hodgson SH, Duncan CJ, Hill AV, Draper SJ.

Immunology. 2014 Apr;141(4):628-44. doi: 10.1111/imm.12226.


Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.

Biswas S, Spencer AJ, Forbes EK, Gilbert SC, Holder AA, Hill AV, Draper SJ.

J Immunol. 2012 May 15;188(10):5041-53. doi: 10.4049/jimmunol.1101106.


Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1.

Burns JM Jr, Flaherty PR, Romero MM, Weidanz WP.

Vaccine. 2003 May 16;21(17-18):1843-52.


Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.

Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM.

Vaccine. 2010 Apr 1;28(16):2818-26. doi: 10.1016/j.vaccine.2010.02.004.


Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.

Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, Chitnis CE, Chauhan VS.

Vaccine. 2007 Jul 9;25(28):5166-74.


Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.

Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, Irving DO, Briggs WR, Mai A, Ginny M, Adiguma T, Rare L, Giddy A, Reber-Liske R, Stuerchler D, Alpers MP.

Vaccine. 2000 May 22;18(23):2504-11.


Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology.

Okitsu SL, Mueller MS, Amacker M, Vogel D, Westerfeld N, Robinson JA, Zurbriggen R, Pluschke G.

Hum Vaccin. 2008 Mar-Apr;4(2):106-14.


Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.

Elias SC, Collins KA, Halstead FD, Choudhary P, Bliss CM, Ewer KJ, Sheehy SH, Duncan CJ, Biswas S, Hill AV, Draper SJ.

J Immunol. 2013 Feb 1;190(3):1135-47. doi: 10.4049/jimmunol.1201455.


Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.

Tamminga C, Sedegah M, Maiolatesi S, Fedders C, Reyes S, Reyes A, Vasquez C, Alcorta Y, Chuang I, Spring M, Kavanaugh M, Ganeshan H, Huang J, Belmonte M, Abot E, Belmonte A, Banania J, Farooq F, Murphy J, Komisar J, Richie NO, Bennett J, Limbach K, Patterson NB, Bruder JT, Shi M, Miller E, Dutta S, Diggs C, Soisson LA, Hollingdale MR, Epstein JE, Richie TL.

Hum Vaccin Immunother. 2013 Oct;9(10):2165-77. doi: 10.4161/hv.24941.


Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.

Cort├ęs A, Mellombo M, Masciantonio R, Murphy VJ, Reeder JC, Anders RF.

Infect Immun. 2005 Jan;73(1):422-30.

Items per page

Supplemental Content

Support Center